PRODUCT INFORMATION



Paquinimod

Item No. 28443

CAS Registry No.: Formal Name:	248282-01-1 N,5-diethyl-1,2-dihydro-4- hydroxy-1-methyl-2-oxo-N- phenyl-3-quinolinecarboxamide	он о
Synonym:	ABR-25757	L L Ĭ L IJ
MF:	$C_{21}H_{22}N_2O_3$	N N
FW:	350.4	
Purity:	≥98%	
UV/Vis.:	λ _{max} : 233, 298 nm	
Supplied as:	A solid	
Storage:	-20°C	
Stability:	≥4 years	
Information represents the number operifications. Batch experific analytical results are provided on each contificate of an		

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Paquinimod is supplied as a solid. A stock solution may be made by dissolving the paquinimod in the solvent of choice, which should be purged with an inert gas. Paquinimod is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of paquinimod in these solvents is approximately 3, 15, and 20 mg/ml, respectively.

Paquinimod is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, paquinimod should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Paquinimod has a solubility of approximately 0.16 mg/ml in a 1:5 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Paquinimod is an immunomodulator.¹⁻⁴ In vivo, paquinimod reduces splenic counts of Ly6ChiCD115+ inflammatory monocytes and CD11b⁺CD11c⁺ dendritic cells in a mouse model of experimental autoimmune encephalomyelitis (EAE).¹ Paquinimod (25 mg/kg per day) reduces hepatic fibrosis and accumulation of inflammatory monocytes and neutrophils in the N-IF mouse model of liver fibrosis.² It delays disease onset and decreases insulitis in non-obese diabetic (NOD) mice.³ Paquinimod (5 and 25 mg/kg) reduces skin thickness, the number of myofibroblasts, and autoantibody production in the tight skin 1 mouse model of systemic sclerosis.⁴

References

- 1. Helmersson, S., Sundstedt, A., Deronic, A., et al. Amelioration of experimental autoimmune encephalomyelitis by the quinoline-3-carboxamide paquinimod: Reduced priming of proinflammatory effector CD4⁺ T cells. Am. J. Pathol. 182(5), 1671-1680 (2013).
- 2. Fransén Pettersson, N., Deronic, A., Hannibal, T.D., et al. The immunomodulatory guinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis. PLoS One 13(9), e0203228 (2018).
- 3. Tahvili, S., Törngren, M., Holmberg, D., et al. Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse. PLoS One 13(5), e0196598 (2018).
- 4. Stenström, M., Nyhlén, H.C., Törngren, M., et al. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis. J. Dermatol. Sci. 83(1), 52-59 (2016).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/05/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM